Skip to main content
Top
Published in: BMC Gastroenterology 1/2024

Open Access 01-12-2024 | Acute Liver Failure | Research

The burden and predictors of 30-day unplanned readmission in patients with acute liver failure: a national representative database study

Authors: Xianbin Xu, Kai Gong, Liang Hong, Xia Yu, Huilan Tu, Yan Lan, Junjie Yao, Shaoheng Ye, Haoda Weng, Zhiwei Li, Yu Shi, Jifang Sheng

Published in: BMC Gastroenterology | Issue 1/2024

Login to get access

Abstract

Background

Liver diseases were significant source of early readmission burden. This study aimed to evaluate the 30-day unplanned readmission rates, causes of readmissions, readmission costs, and predictors of readmission in patients with acute liver failure (ALF).

Methods

Patients admitted for ALF from 2019 National Readmission Database were enrolled. Weighted multivariable logistic regression models were applied and based on Directed Acyclic Graphs. Incidence, causes, cost, and predictors of 30-day unplanned readmissions were identified.

Results

A total of 3,281 patients with ALF were enrolled, of whom 600 (18.3%) were readmitted within 30 days. The mean time from discharge to early readmission was 12.6 days. The average hospital cost and charge of readmission were $19,629 and $86,228, respectively. The readmissions were mainly due to liver-related events (26.6%), followed by infection (20.9%). The predictive factors independently associated with readmissions were age, male sex (OR 1.227, 95% CI 1.023–1.472; P = 0.028), renal failure (OR 1.401, 95% CI 1.139–1.723; P = 0.001), diabetes with chronic complications (OR 1.327, 95% CI 1.053–1.672; P = 0.017), complicated hypertension (OR 1.436, 95% CI 1.111–1.857; P = 0.006), peritoneal drainage (OR 1.600, 95% CI 1.092–2.345; P = 0.016), etc.

Conclusions

Patients with ALF are at relatively high risk of early readmission, which imposes a heavy medical and economic burden on society. We need to increase the emphasis placed on early readmission of patients with ALF and establish clinical strategies for their management.
Appendix
Available only for authorised users
Literature
4.
go back to reference Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2021. Gastroenterology. 2022;162(2):621–44.CrossRefPubMed Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2021. Gastroenterology. 2022;162(2):621–44.CrossRefPubMed
5.
go back to reference Krishna SG, Chu BK, Blaszczak AM, et al. Hospital outcomes and early readmission for the most common gastrointestinal and liver diseases in the United States: implications for healthcare delivery. World J Gastrointest Surg. 2021;13(2):141–52.CrossRefPubMedPubMedCentral Krishna SG, Chu BK, Blaszczak AM, et al. Hospital outcomes and early readmission for the most common gastrointestinal and liver diseases in the United States: implications for healthcare delivery. World J Gastrointest Surg. 2021;13(2):141–52.CrossRefPubMedPubMedCentral
6.
go back to reference Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. Gastroenterology. 2019;156(1):254–e27211.CrossRefPubMed Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: Update 2018. Gastroenterology. 2019;156(1):254–e27211.CrossRefPubMed
7.
go back to reference Garg SK, Goyal H, Obaitan I, et al. Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the United States National readmissions Database. Ann Transl Med. 2021;9(13):1052–1052.CrossRefPubMedPubMedCentral Garg SK, Goyal H, Obaitan I, et al. Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the United States National readmissions Database. Ann Transl Med. 2021;9(13):1052–1052.CrossRefPubMedPubMedCentral
8.
go back to reference Chirapongsathorn S, Krittanawong C, Enders FT, et al. Incidence and cost analysis of hospital admission and 30-day readmission among patients with cirrhosis. Hepatol Commun. 2018;2(2):188–98.CrossRefPubMedPubMedCentral Chirapongsathorn S, Krittanawong C, Enders FT, et al. Incidence and cost analysis of hospital admission and 30-day readmission among patients with cirrhosis. Hepatol Commun. 2018;2(2):188–98.CrossRefPubMedPubMedCentral
9.
go back to reference Mumtaz K, Issak A, Porter K, et al. Validation of risk score in Predicting Early readmissions in Decompensated Cirrhotic patients: a Model based on the administrative database. Hepatology. 2019;70(2):630–9.CrossRefPubMed Mumtaz K, Issak A, Porter K, et al. Validation of risk score in Predicting Early readmissions in Decompensated Cirrhotic patients: a Model based on the administrative database. Hepatology. 2019;70(2):630–9.CrossRefPubMed
11.
go back to reference Weiler N, Schlotmann A, Schnitzbauer AA, et al. The epidemiology of Acute Liver failure. Dtsch Arztebl Int. 2020;117(4):43–50.PubMedPubMedCentral Weiler N, Schlotmann A, Schnitzbauer AA, et al. The epidemiology of Acute Liver failure. Dtsch Arztebl Int. 2020;117(4):43–50.PubMedPubMedCentral
14.
go back to reference Jencks SF, Williams Mv, Coleman EA. Rehospitalizations among patients in the Medicare Fee-for-Service Program. N Engl J Med. 2009;360(14):1418–28.CrossRefPubMed Jencks SF, Williams Mv, Coleman EA. Rehospitalizations among patients in the Medicare Fee-for-Service Program. N Engl J Med. 2009;360(14):1418–28.CrossRefPubMed
15.
go back to reference Zuckerman RB, Sheingold SH, Orav EJ, Ruhter J, Epstein AM. Readmissions, Observation, and the Hospital readmissions Reduction Program. N Engl J Med. 2016;374(16):1543–51.CrossRefPubMed Zuckerman RB, Sheingold SH, Orav EJ, Ruhter J, Epstein AM. Readmissions, Observation, and the Hospital readmissions Reduction Program. N Engl J Med. 2016;374(16):1543–51.CrossRefPubMed
16.
go back to reference Berry JG, Gay JC, Joynt Maddox K et al. Age trends in 30 day hospital readmissions: US national retrospective analysis. BMJ. 2018;360. Berry JG, Gay JC, Joynt Maddox K et al. Age trends in 30 day hospital readmissions: US national retrospective analysis. BMJ. 2018;360.
17.
go back to reference Dharel N, Bajaj JS. Antibiotic prophylaxis in acute liver failure: friend or foe? Clin Gastroenterol Hepatol. 2014;12(11):1950–2.CrossRefPubMed Dharel N, Bajaj JS. Antibiotic prophylaxis in acute liver failure: friend or foe? Clin Gastroenterol Hepatol. 2014;12(11):1950–2.CrossRefPubMed
18.
go back to reference Antoniades CG, Berry PA, Davies ET, et al. Reduced monocyte HLA-DR expression: a novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure. Hepatology. 2006;44(1):34–43.CrossRefPubMed Antoniades CG, Berry PA, Davies ET, et al. Reduced monocyte HLA-DR expression: a novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure. Hepatology. 2006;44(1):34–43.CrossRefPubMed
19.
go back to reference Wyke RJ, Rajkovic I, Eddleston ALWF, Williams R. Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure. Gut. 1980;21(8):643–9.CrossRefPubMedPubMedCentral Wyke RJ, Rajkovic I, Eddleston ALWF, Williams R. Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure. Gut. 1980;21(8):643–9.CrossRefPubMedPubMedCentral
20.
go back to reference Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(3):505–e5121.CrossRefPubMed Garg V, Garg H, Khan A, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(3):505–e5121.CrossRefPubMed
21.
go back to reference Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver failure Study Group. Crit Care Med. 2007;35(11):2498–508.CrossRefPubMed Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver failure Study Group. Crit Care Med. 2007;35(11):2498–508.CrossRefPubMed
22.
go back to reference CJ K. Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure: a retrospective cohort study. Clin Gastroenterol Hepatol. 2014;12(11):1942–e19491.CrossRef CJ K. Effects of antimicrobial prophylaxis and blood stream infections in patients with acute liver failure: a retrospective cohort study. Clin Gastroenterol Hepatol. 2014;12(11):1942–e19491.CrossRef
23.
go back to reference Berman K, Tandra S, Forssell K, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol. 2011;9(3):254–9.CrossRefPubMed Berman K, Tandra S, Forssell K, et al. Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol. 2011;9(3):254–9.CrossRefPubMed
24.
go back to reference Wendon J. EASL Clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047–81.CrossRefPubMed Wendon J. EASL Clinical practical guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047–81.CrossRefPubMed
25.
go back to reference Tujios SR, Hynan LS, Vazquez MA, et al. Risk factors and outcomes of acute kidney injury in patients with acute liver failure. Clin Gastroenterol Hepatol. 2015;13(2):352–9.CrossRefPubMed Tujios SR, Hynan LS, Vazquez MA, et al. Risk factors and outcomes of acute kidney injury in patients with acute liver failure. Clin Gastroenterol Hepatol. 2015;13(2):352–9.CrossRefPubMed
Metadata
Title
The burden and predictors of 30-day unplanned readmission in patients with acute liver failure: a national representative database study
Authors
Xianbin Xu
Kai Gong
Liang Hong
Xia Yu
Huilan Tu
Yan Lan
Junjie Yao
Shaoheng Ye
Haoda Weng
Zhiwei Li
Yu Shi
Jifang Sheng
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2024
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-024-03249-0

Other articles of this Issue 1/2024

BMC Gastroenterology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine